Health Affairs, Vol. 29, No. 9, September 2010
8 Pages Posted: 16 Nov 2010 Last revised: 8 Aug 2015
Date Written: November 15, 2010
The world faces a worsening public health crisis: A growing number of bacteria are resistant to available antibiotics. Yet there are few new antibiotics in the development pipeline to take the place of these increasingly ineffective drugs. We review a number of proposals intended to bolster drug development, including such financial incentives for pharmaceutical manufacturers as extending the effective patent life for new antibiotics. However, such strategies directly conflict with the clear need to reduce unnecessary antibiotic prescriptions and could actually increase prescription use. As an alternative, we recommend a two-prong, "integrated" strategy. This would increase reimbursement for the appropriate, evidence-based use of antibiotics that also met specific public health goals - such as reducing illness levels while limiting antibiotic resistance.
Keywords: antibiotic resistance, antibiotics, drug development, patenting of antibiotics
JEL Classification: K11, K19, K323, K32, K33, K39
Suggested Citation: Suggested Citation
Outterson, Kevin and Kesselheim, Aaron S., Fighting Antibiotic Resistance: Marrying New Financial Incentives to Meeting Public Health Goals (November 15, 2010). Health Affairs, Vol. 29, No. 9, September 2010 ; Boston Univ. School of Law Working Paper No. 10-40. Available at SSRN: https://ssrn.com/abstract=1709389